231 related articles for article (PubMed ID: 22928601)
1. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.
Nguyen DN; Heaphy CM; de Wilde RF; Orr BA; Odia Y; Eberhart CG; Meeker AK; Rodriguez FJ
Brain Pathol; 2013 May; 23(3):237-43. PubMed ID: 22928601
[TBL] [Abstract][Full Text] [Related]
2. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
Abedalthagafi M; Phillips JJ; Kim GE; Mueller S; Haas-Kogen DA; Marshall RE; Croul SE; Santi MR; Cheng J; Zhou S; Sullivan LM; Martinez-Lage M; Judkins AR; Perry A
Mod Pathol; 2013 Nov; 26(11):1425-32. PubMed ID: 23765250
[TBL] [Abstract][Full Text] [Related]
3. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
4. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
5. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
[TBL] [Abstract][Full Text] [Related]
6. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
[TBL] [Abstract][Full Text] [Related]
7. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
[TBL] [Abstract][Full Text] [Related]
8. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.
Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M;
Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351
[TBL] [Abstract][Full Text] [Related]
9. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
[TBL] [Abstract][Full Text] [Related]
10. Altered telomeres in tumors with ATRX and DAXX mutations.
Heaphy CM; de Wilde RF; Jiao Y; Klein AP; Edil BH; Shi C; Bettegowda C; Rodriguez FJ; Eberhart CG; Hebbar S; Offerhaus GJ; McLendon R; Rasheed BA; He Y; Yan H; Bigner DD; Oba-Shinjo SM; Marie SK; Riggins GJ; Kinzler KW; Vogelstein B; Hruban RH; Maitra A; Papadopoulos N; Meeker AK
Science; 2011 Jul; 333(6041):425. PubMed ID: 21719641
[TBL] [Abstract][Full Text] [Related]
11. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
[TBL] [Abstract][Full Text] [Related]
12. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
13. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM
Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317
[TBL] [Abstract][Full Text] [Related]
15. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
16. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
17. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
[TBL] [Abstract][Full Text] [Related]
18. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
19. A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.
Borodovsky A; Meeker AK; Kirkness EF; Zhao Q; Eberhart CG; Gallia GL; Riggins GJ
J Neurooncol; 2015 Feb; 121(3):479-87. PubMed ID: 25471051
[TBL] [Abstract][Full Text] [Related]
20. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
